

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/820,618
				Filing Date	April 7, 2004
				First Named Inventor	HUANG, YADONG
				Group Art Unit	To Be Assigned
Sheet	2	of	2	Examiner Name	To Be Assigned
				Attorney Docket Number	UCAL-217CON

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Patent Abstracts of Japan, Vol. 1999, No. 5, May 31, 1991 & JP 11 049739, Nippon Steel Corp, February 23, 1999	
		GOLABEK Adam, et al., "Sodium Dodecyl Sulfate-Resistant Complexes of Alzheimer's Amyloid beta-peptide with the N-Terminal, Receptor Binding Domain of Apolipoprotein E" Biophysical Journal, Vol. 79, No. 2, August 2000, pgs. 1008-1015	
		MARQUES M. A. et al., "A Thrombin Cleavage Fragment of Apolipoprotein E Exhibits Isoform-Specific Neurotoxicity" Neuroreport, Rapid Communications of Oxford, Oxford GB, Vol.7, No. 15-17, November 4, 1996	
		Aleshkov Sergel B. et al., "Contribution of Cyteine 158, the Glycosylation Site Theonine 194, the Amino- and Carboxy-Terminal Domains of Apolipoprotein E in the Binding to Amyloid Peptide Beta (1-40)" Biochemistry, Vol. 38, No. 28, July 13, 1999	
		Tolar M. et al., "Neurotoxicity of the 11 KDA Thrombin-Cleavage Fragment of Apolipoprotein E and Related Synthetic Peptides Is Receptor-Mediated", Journal of Neuroscience, New York, NY, Vol. 17, No. 15, pgs. 5678-5686 (1997)	
		Dong L. M. et al., "Human Apolipoprotein E Role of Arginine 61 in Mediating the Lipoprotein Preferences of the E3 and E4 Isoforms", Journal of Biological Chemistry, The American Society of Biological Chemists, Inc., U.S. Vol. 269, No. 35, September 2, 1994	

Examiner Signature	/Michael Pak/	Date Considered	12/28/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MP/